EMEA (Europe, Middle East and Africa) Recombinant Peptides Market Report 2017

  • KMI-167734
  • Sep 2017
  • 103 pages
  • Pharmaceutical
In this report, the EMEA Recombinant Peptides market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.



Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Recombinant Peptides for these regions, from 2012 to 2022 (forecast)

Europe: Germany, France, UK, Russia, Italy and Benelux;

Middle East: Saudi Arabia, Israel, UAE and Iran;

Africa: South Africa, Nigeria, Egypt and Algeria.



EMEA Recombinant Peptides market competition by top manufacturers/players, with Recombinant Peptides sales volume (K MT), price (USD/MT), revenue (Million USD) and market share for each manufacturer/player; the top players including

Sandoz Pharma

Stada Arzneimittel

Amgen

Hospira

Actavis

Cipla Ltd.

Wockhardt Ltd.

Biocon Ltd.



On the basis of product, this report displays the sales volume (K MT), revenue (Million USD), product price (USD/MT), market share and growth rate of each type, primarily split into

Glucagon

Calcitonin

Other



On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K MT), market share and growth rate of Recombinant Peptides for each application, including

Oncology

Blood Disorders

Infectious Diseases

Autoimmune Diseases

Other



If you have any special requirements, please let us know and we will offer you the report as you want.



Table of Contents



EMEA (Europe, Middle East and Africa) Recombinant Peptides Market Report 2017

1 Recombinant Peptides Overview

1.1 Product Overview and Scope of Recombinant Peptides

1.2 Classification of Recombinant Peptides

1.2.1 EMEA Recombinant Peptides Market Size (Sales) Comparison by Type (2012-2022)

1.2.2 EMEA Recombinant Peptides Market Size (Sales) Market Share by Type (Product Category) in 2016

1.2.3 Glucagon

1.2.4 Calcitonin

1.2.5 Other

1.3 EMEA Recombinant Peptides Market by Application/End Users

1.3.1 EMEA Recombinant Peptides Sales (Volume) and Market Share Comparison by Application (2012-2022

1.3.2 Oncology

1.3.3 Blood Disorders

1.3.4 Infectious Diseases

1.3.5 Autoimmune Diseases

1.3.6 Other

1.4 EMEA Recombinant Peptides Market by Region

1.4.1 EMEA Recombinant Peptides Market Size (Value) Comparison by Region (2012-2022)

1.4.2 Europe Status and Prospect (2012-2022)

1.4.3 Middle East Status and Prospect (2012-2022)

1.4.4 Africa Status and Prospect (2012-2022)

1.5 EMEA Market Size (Value and Volume) of Recombinant Peptides (2012-2022)

1.5.1 EMEA Recombinant Peptides Sales and Growth Rate (2012-2022)

1.5.2 EMEA Recombinant Peptides Revenue and Growth Rate (2012-2022)



2 EMEA Recombinant Peptides Competition by Manufacturers/Players/Suppliers, Region, Type and Application

2.1 EMEA Recombinant Peptides Market Competition by Players/Manufacturers

2.1.1 EMEA Recombinant Peptides Sales Volume and Market Share of Major Players (2012-2017)

2.1.2 EMEA Recombinant Peptides Revenue and Share by Players (2012-2017)

2.1.3 EMEA Recombinant Peptides Sale Price by Players (2012-2017)

2.2 EMEA Recombinant Peptides (Volume and Value) by Type/Product Category

2.2.1 EMEA Recombinant Peptides Sales and Market Share by Type (2012-2017)

2.2.2 EMEA Recombinant Peptides Revenue and Market Share by Type (2012-2017)

2.2.3 EMEA Recombinant Peptides Sale Price by Type (2012-2017)

2.3 EMEA Recombinant Peptides (Volume) by Application

2.4 EMEA Recombinant Peptides (Volume and Value) by Region

2.4.1 EMEA Recombinant Peptides Sales and Market Share by Region (2012-2017)

2.4.2 EMEA Recombinant Peptides Revenue and Market Share by Region (2012-2017)

2.4.3 EMEA Recombinant Peptides Sales Price by Region (2012-2017)



3 Europe Recombinant Peptides (Volume, Value and Sales Price), by Players, Countries, Type and Application

3.1 Europe Recombinant Peptides Sales and Value (2012-2017)

3.1.1 Europe Recombinant Peptides Sales Volume and Growth Rate (2012-2017)

3.1.2 Europe Recombinant Peptides Revenue and Growth Rate (2012-2017)

3.2 Europe Recombinant Peptides Sales and Market Share by Type

3.3 Europe Recombinant Peptides Sales and Market Share by Application

3.4 Europe Recombinant Peptides Sales Volume and Value (Revenue) by Countries

3.4.1 Europe Recombinant Peptides Sales Volume by Countries (2012-2017)

3.4.2 Europe Recombinant Peptides Revenue by Countries (2012-2017)

3.4.3 Germany Recombinant Peptides Sales and Growth Rate (2012-2017)

3.4.4 France Recombinant Peptides Sales and Growth Rate (2012-2017)

3.4.5 UK Recombinant Peptides Sales and Growth Rate (2012-2017)

3.4.6 Russia Recombinant Peptides Sales and Growth Rate (2012-2017)

3.4.7 Italy Recombinant Peptides Sales and Growth Rate (2012-2017)

3.4.8 Benelux Recombinant Peptides Sales and Growth Rate (2012-2017)



4 Middle East Recombinant Peptides (Volume, Value and Sales Price), by Region, Type and Application

4.1 Middle East Recombinant Peptides Sales and Value (2012-2017)

4.1.1 Middle East Recombinant Peptides Sales Volume and Growth Rate (2012-2017)

4.1.2 Middle East Recombinant Peptides Revenue and Growth Rate (2012-2017)

4.2 Middle East Recombinant Peptides Sales and Market Share by Type

4.3 Middle East Recombinant Peptides Sales and Market Share by Application

4.4 Middle East Recombinant Peptides Sales Volume and Value (Revenue) by Countries

4.4.1 Middle East Recombinant Peptides Sales Volume by Countries (2012-2017)

4.4.2 Middle East Recombinant Peptides Revenue by Countries (2012-2017)

4.4.3 Saudi Arabia Recombinant Peptides Sales and Growth Rate (2012-2017)

4.4.4 Israel Recombinant Peptides Sales and Growth Rate (2012-2017)

4.4.5 UAE Recombinant Peptides Sales and Growth Rate (2012-2017)

4.4.6 Iran Recombinant Peptides Sales and Growth Rate (2012-2017)



5 Africa Recombinant Peptides (Volume, Value and Sales Price) by Players, Countries, Type and Application

5.1 Africa Recombinant Peptides Sales and Value (2012-2017)

5.1.1 Africa Recombinant Peptides Sales Volume and Growth Rate (2012-2017)

5.1.2 Africa Recombinant Peptides Revenue and Growth Rate (2012-2017)

5.2 Africa Recombinant Peptides Sales and Market Share by Type

5.3 Africa Recombinant Peptides Sales and Market Share by Application

5.4 Africa Recombinant Peptides Sales Volume and Value (Revenue) by Countries

5.4.1 Africa Recombinant Peptides Sales Volume by Countries (2012-2017)

5.4.2 Africa Recombinant Peptides Revenue by Countries (2012-2017)

5.4.3 South Africa Recombinant Peptides Sales and Growth Rate (2012-2017)

5.4.4 Nigeria Recombinant Peptides Sales and Growth Rate (2012-2017)

5.4.5 Egypt Recombinant Peptides Sales and Growth Rate (2012-2017)

5.4.6 Algeria Recombinant Peptides Sales and Growth Rate (2012-2017)



6 EMEA Recombinant Peptides Manufacturers/Players Profiles and Sales Data

6.1 Sandoz Pharma

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Recombinant Peptides Product Type, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Sandoz Pharma Recombinant Peptides Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 Stada Arzneimittel

6.2.1 Company Basic Information, Manufacturing Base and Competitors

6.2.2 Recombinant Peptides Product Type, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Stada Arzneimittel Recombinant Peptides Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 Amgen

6.3.1 Company Basic Information, Manufacturing Base and Competitors

6.3.2 Recombinant Peptides Product Type, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Amgen Recombinant Peptides Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

6.4 Hospira

6.4.1 Company Basic Information, Manufacturing Base and Competitors

6.4.2 Recombinant Peptides Product Type, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Hospira Recombinant Peptides Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

6.5 Actavis

6.5.1 Company Basic Information, Manufacturing Base and Competitors

6.5.2 Recombinant Peptides Product Type, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Actavis Recombinant Peptides Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview

6.6 Cipla Ltd.

6.6.1 Company Basic Information, Manufacturing Base and Competitors

6.6.2 Recombinant Peptides Product Type, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 Cipla Ltd. Recombinant Peptides Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

6.7 Wockhardt Ltd.

6.7.1 Company Basic Information, Manufacturing Base and Competitors

6.7.2 Recombinant Peptides Product Type, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 Wockhardt Ltd. Recombinant Peptides Sales, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Main Business/Business Overview

6.8 Biocon Ltd.

6.8.1 Company Basic Information, Manufacturing Base and Competitors

6.8.2 Recombinant Peptides Product Type, Application and Specification

6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 Biocon Ltd. Recombinant Peptides Sales, Revenue, Price and Gross Margin (2012-2017)

6.8.4 Main Business/Business Overview



7 Recombinant Peptides Manufacturing Cost Analysis

7.1 Recombinant Peptides Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Recombinant Peptides



8 Industrial Chain, Sourcing Strategy and Downstream Buyers

8.1 Recombinant Peptides Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Recombinant Peptides Major Manufacturers in 2016

8.4 Downstream Buyers



9 Marketing Strategy Analysis, Distributors/Traders

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List



10 Market Effect Factors Analysis

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change



11 EMEA Recombinant Peptides Market Forecast (2017-2022)

11.1 EMEA Recombinant Peptides Sales, Revenue and Price Forecast (2017-2022)

11.1.1 EMEA Recombinant Peptides Sales and Growth Rate Forecast (2017-2022)

11.1.2 EMEA Recombinant Peptides Revenue and Growth Rate Forecast (2017-2022)

11.1.3 EMEA Recombinant Peptides Price and Trend Forecast (2017-2022)

11.2 EMEA Recombinant Peptides Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.3 Europe Recombinant Peptides Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.4 Middle Eastt Recombinant Peptides Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.5 Africa Recombinant Peptides Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.6 EMEA Recombinant Peptides Sales Forecast by Type (2017-2022)

11.7 EMEA Recombinant Peptides Sales Forecast by Application (2017-2022)



12 Research Findings and Conclusion



13 Appendix

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer





Purchase this Market Research Report



Contact Us


Mannan
Mannan Shaikh
Head-Sales
mansing
Mansingh Surve
Manager-Sales
Vivek
Vivek Pandey
Assistant Manager-Sales
Roshnee
Roshnee Tendulkar
Team Lead-Sales
view